Skip to main content
Erschienen in: International Journal of Hematology 5/2010

01.06.2010 | Original Article

Mutation analysis of factor VIII in Korean patients with severe hemophilia A

verfasst von: Chur-Woo You, Hee-Sook Son, Hee Jin Kim, Eui-Jeon Woo, Soon-Ae Kim, Haing-Woon Baik

Erschienen in: International Journal of Hematology | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Hemophilia A is an X-linked recessive disorder caused by mutations of the factor VIII gene. The mutation spectrum has been reported in various populations, but not in Koreans. Mutation analysis of the factor VIII gene was performed in 22 unrelated Korean patients with severe hemophilia A. We extracted genomic DNA from their blood, and assessed intron inversions, deletions, and point mutations by direct DNA sequencing. A multiplex ligation-dependent probe amplification gene dosage assay was also performed to identify exon deletions. Disease-causing mutations were identified in all patients, of which four cases were previously unreported. Seven intron 22 inversions, nine point mutations (6 nonsense mutations and 3 missense mutations), and four small rearrangements were identified. One multi-exon deletion and one 5′-donor splicing site mutation were also observed. Four novel mutations (one small deletion, one multiple exon deletion, one missense, and one splice site mutation) were detected, and point mutations were predominant (40.9%), followed by intron 22 inversions (31.8%). Further studies are required in order to establish a solid conclusion regarding the prevalence of various mutations in the Korean population.
Literatur
1.
Zurück zum Zitat Kaufman RJ. Advances toward gene therapy for hemophilia at the millennium. Hum Gene Ther. 1999;10:2091–107.CrossRefPubMed Kaufman RJ. Advances toward gene therapy for hemophilia at the millennium. Hum Gene Ther. 1999;10:2091–107.CrossRefPubMed
2.
Zurück zum Zitat Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, et al. Structure of human factor VIII. Nature. 1984;312(5992):337–42.CrossRefPubMed Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, et al. Structure of human factor VIII. Nature. 1984;312(5992):337–42.CrossRefPubMed
3.
Zurück zum Zitat Kemball-Cook G, Tudedenham EGD, Wacey AI. The factor VIII structure and mutation resource site: HAMSTeRS version 4. Nucleic Acids Res. 1998;26(1):216–9.CrossRefPubMed Kemball-Cook G, Tudedenham EGD, Wacey AI. The factor VIII structure and mutation resource site: HAMSTeRS version 4. Nucleic Acids Res. 1998;26(1):216–9.CrossRefPubMed
4.
Zurück zum Zitat Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe hemophilia A. Nat Genet. 1993;5(3):236–41.CrossRefPubMed Lakich D, Kazazian HH Jr, Antonarakis SE, Gitschier J. Inversions disrupting the factor VIII gene are a common cause of severe hemophilia A. Nat Genet. 1993;5(3):236–41.CrossRefPubMed
5.
Zurück zum Zitat Jacquemin M, De Maeyer M, D’Oiron R, Lavend’Homme R, Peerlinck K, Saint-Remy JM. Molecular mechanisms of mild and moderate hemophilia A. J Thromb Haemost. 2003;1(3):456–63.CrossRefPubMed Jacquemin M, De Maeyer M, D’Oiron R, Lavend’Homme R, Peerlinck K, Saint-Remy JM. Molecular mechanisms of mild and moderate hemophilia A. J Thromb Haemost. 2003;1(3):456–63.CrossRefPubMed
6.
Zurück zum Zitat Oldenburg J, Ananyeva NM, Saenko EL. Molecular basis of haemophilia A. Haemophilia. 2004;10(Suppl 4):133–9.CrossRefPubMed Oldenburg J, Ananyeva NM, Saenko EL. Molecular basis of haemophilia A. Haemophilia. 2004;10(Suppl 4):133–9.CrossRefPubMed
7.
Zurück zum Zitat White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, Factor VIII and Factor IX Subcommittee. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the international society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.PubMed White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, Factor VIII and Factor IX Subcommittee. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the international society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560.PubMed
8.
Zurück zum Zitat Liu Q, Nozari G, Sommer SS. Single-tube polymerase chain reaction for rapid diagnosis of the inversion hotspot of mutation in hemophilia A. Blood. 1998;92(4):1458–9.PubMed Liu Q, Nozari G, Sommer SS. Single-tube polymerase chain reaction for rapid diagnosis of the inversion hotspot of mutation in hemophilia A. Blood. 1998;92(4):1458–9.PubMed
9.
Zurück zum Zitat Liu Q, Sommer SS. Subcycling-PCR for multiplex long-distance amplification of regions with high and low GC content: application to the inversion hotspot in the factor VIII gene. Biotechniques. 1998;25(6):1022–8.PubMed Liu Q, Sommer SS. Subcycling-PCR for multiplex long-distance amplification of regions with high and low GC content: application to the inversion hotspot in the factor VIII gene. Biotechniques. 1998;25(6):1022–8.PubMed
10.
Zurück zum Zitat Vidal F, Farssac E, Altisent C, Puig L, Gallardo D. Rapid hemophilia A molecular diagnosis by a simple DNA sequencing procedure: identification of 14 novel mutations. Thromb Haemost. 2001;85(4):580–3.PubMed Vidal F, Farssac E, Altisent C, Puig L, Gallardo D. Rapid hemophilia A molecular diagnosis by a simple DNA sequencing procedure: identification of 14 novel mutations. Thromb Haemost. 2001;85(4):580–3.PubMed
11.
Zurück zum Zitat Bagnall RD, Waseem N, Green PM, Giannelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood. 2002;99(1):168–74.CrossRefPubMed Bagnall RD, Waseem N, Green PM, Giannelli F. Recurrent inversion breaking intron 1 of the factor VIII gene is a frequent cause of severe hemophilia A. Blood. 2002;99(1):168–74.CrossRefPubMed
12.
Zurück zum Zitat Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30(12):e57.CrossRefPubMed Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30(12):e57.CrossRefPubMed
13.
Zurück zum Zitat Bogdanova N, Markoff A, Pollmann H, Nowak-Göttl U, Eisert R, Wermes C, et al. Spectrum of molecular defects and mutation detection rate in patients with severe hemophilia A. Hum Mutat. 2005;26(3):249–54.CrossRefPubMed Bogdanova N, Markoff A, Pollmann H, Nowak-Göttl U, Eisert R, Wermes C, et al. Spectrum of molecular defects and mutation detection rate in patients with severe hemophilia A. Hum Mutat. 2005;26(3):249–54.CrossRefPubMed
14.
Zurück zum Zitat Antonarakis SE, Rossiter JP, Young M, Horst J, de Moerloose P, Sommer SS, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood. 1995;86(6):2206–12.PubMed Antonarakis SE, Rossiter JP, Young M, Horst J, de Moerloose P, Sommer SS, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood. 1995;86(6):2206–12.PubMed
15.
Zurück zum Zitat Fukuda K, Naka H, Morichika S, Shibata M, Tanaka I, Shima M, et al. Inversions of the factor VIII gene in Japanese patients with severe hemophilia A. Int J Hematol. 2004;79(3):303–6.CrossRefPubMed Fukuda K, Naka H, Morichika S, Shibata M, Tanaka I, Shima M, et al. Inversions of the factor VIII gene in Japanese patients with severe hemophilia A. Int J Hematol. 2004;79(3):303–6.CrossRefPubMed
16.
Zurück zum Zitat Pattinson JK, Millar DS, McVey JH, Grundy CB, Wieland K, Mibashan RS, et al. The molecular genetic analysis of hemophilia A: a direct search strategy for the detection of point mutations in the factor VIII gene. Blood. 1990;76(11):2242–8.PubMed Pattinson JK, Millar DS, McVey JH, Grundy CB, Wieland K, Mibashan RS, et al. The molecular genetic analysis of hemophilia A: a direct search strategy for the detection of point mutations in the factor VIII gene. Blood. 1990;76(11):2242–8.PubMed
17.
Zurück zum Zitat Margaglione M, Castaman G, Morfini M, Rocino A, Santagostino E, Tagariello G, AICE-Genetics Study Group, et al. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica. 2008;93(5):722–8.CrossRefPubMed Margaglione M, Castaman G, Morfini M, Rocino A, Santagostino E, Tagariello G, AICE-Genetics Study Group, et al. The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype. Haematologica. 2008;93(5):722–8.CrossRefPubMed
18.
Zurück zum Zitat Duncan BK, Miller JH. Mutagenic deamination of cytosine residues in DNA. Nature. 1980;287(5782):560–1.CrossRefPubMed Duncan BK, Miller JH. Mutagenic deamination of cytosine residues in DNA. Nature. 1980;287(5782):560–1.CrossRefPubMed
19.
Zurück zum Zitat Higuchi M, Kazazian HH Jr, Kasch L, Warren TC, McGinniss MJ, Phillips JA 3rd, et al. Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the factor VIII gene. Proc Natl Acad Sci USA. 1991;88(16):7405–9.CrossRefPubMed Higuchi M, Kazazian HH Jr, Kasch L, Warren TC, McGinniss MJ, Phillips JA 3rd, et al. Molecular characterization of severe hemophilia A suggests that about half the mutations are not within the coding regions and splice junctions of the factor VIII gene. Proc Natl Acad Sci USA. 1991;88(16):7405–9.CrossRefPubMed
20.
Zurück zum Zitat Wakabayashi H, Fay PJ. Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa. J Biol Chem. 2008;283(17):11645–51.CrossRefPubMed Wakabayashi H, Fay PJ. Identification of residues contributing to A2 domain-dependent structural stability in factor VIII and factor VIIIa. J Biol Chem. 2008;283(17):11645–51.CrossRefPubMed
21.
Zurück zum Zitat Naylor JA, Green PM, Rizza CR, Giannelli F. Analysis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients. Hum Mol Genet. 1993;2(1):11–7.CrossRefPubMed Naylor JA, Green PM, Rizza CR, Giannelli F. Analysis of factor VIII mRNA reveals defects in everyone of 28 haemophilia A patients. Hum Mol Genet. 1993;2(1):11–7.CrossRefPubMed
22.
Zurück zum Zitat Timur AA, Gürgey A, Aktuglu G, Kavakli K, Canatan D, Olek K, Caglayan SH. Molecular pathology of haemophilia A in Turkish patients: identification of 36 independent mutations. Haemophilia. 2001;7(5):475–81.CrossRefPubMed Timur AA, Gürgey A, Aktuglu G, Kavakli K, Canatan D, Olek K, Caglayan SH. Molecular pathology of haemophilia A in Turkish patients: identification of 36 independent mutations. Haemophilia. 2001;7(5):475–81.CrossRefPubMed
23.
Zurück zum Zitat Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG, Kemball-Cook G. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood. 1997;89:2413–21.PubMed Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG, Kemball-Cook G. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood. 1997;89:2413–21.PubMed
24.
Zurück zum Zitat Goodeve AC, Williams I, Bray GL, Peake IR. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thromb Haemost. 2000;83(6):844–8.PubMed Goodeve AC, Williams I, Bray GL, Peake IR. Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with recombinant factor VIII (Recombinate). Recombinate PUP Study Group. Thromb Haemost. 2000;83(6):844–8.PubMed
25.
Zurück zum Zitat Vidal F, Farssac E, Altisent C, Puig L, Gallardo D. Rapid hemophilia A molecular diagnosis by a simple DNA sequencing procedure: identification of 14 novel mutations. Thromb Haemost. 2001;85(4):580–3 (Erratum in: Thromb Haemost 2001;86(2):727). Vidal F, Farssac E, Altisent C, Puig L, Gallardo D. Rapid hemophilia A molecular diagnosis by a simple DNA sequencing procedure: identification of 14 novel mutations. Thromb Haemost. 2001;85(4):580–3 (Erratum in: Thromb Haemost 2001;86(2):727).
26.
Zurück zum Zitat Theophilus BD, Enayat MS, Williams MD, Hill FG. Site and type of mutations in the factor VIII gene in patients and carriers of haemophilia A. Haemophilia. 2001;7(4):381–91.CrossRefPubMed Theophilus BD, Enayat MS, Williams MD, Hill FG. Site and type of mutations in the factor VIII gene in patients and carriers of haemophilia A. Haemophilia. 2001;7(4):381–91.CrossRefPubMed
27.
Zurück zum Zitat Liu ML, Nakaya S, Thompson AR. Non-inversion factor VIII mutations in 80 hemophilia A families including 24 with alloimmune responses. Thromb Haemost. 2002;87(2):273–6.PubMed Liu ML, Nakaya S, Thompson AR. Non-inversion factor VIII mutations in 80 hemophilia A families including 24 with alloimmune responses. Thromb Haemost. 2002;87(2):273–6.PubMed
28.
Zurück zum Zitat Cutler JA, Mitchell MJ, Smith MP, Savidge GF. The identification and classification of 41 novel mutations in the factor VIII gene (F8C). Hum Mutat. 2002;19(3):274–8.CrossRefPubMed Cutler JA, Mitchell MJ, Smith MP, Savidge GF. The identification and classification of 41 novel mutations in the factor VIII gene (F8C). Hum Mutat. 2002;19(3):274–8.CrossRefPubMed
29.
Zurück zum Zitat Bogdanova N, Markoff A, Pollmann H, Nowak-Göttl U, Eisert R, Dworniczak B, Eigel A, Horst J. Prevalence of small rearrangements in the factor VIII gene F8C among patients with severe hemophilia A. Hum Mutat. 2002;20(3):236–7.CrossRefPubMed Bogdanova N, Markoff A, Pollmann H, Nowak-Göttl U, Eisert R, Dworniczak B, Eigel A, Horst J. Prevalence of small rearrangements in the factor VIII gene F8C among patients with severe hemophilia A. Hum Mutat. 2002;20(3):236–7.CrossRefPubMed
30.
Zurück zum Zitat Oldenburg J, El-Maarri O. New insight into the molecular basis of hemophilia A. Int J Hematol. 2006;83(2):96–102.CrossRefPubMed Oldenburg J, El-Maarri O. New insight into the molecular basis of hemophilia A. Int J Hematol. 2006;83(2):96–102.CrossRefPubMed
31.
Zurück zum Zitat Burns DP, Temin HM. High rates of frameshift mutations within homo-oligomeric runs during a single cycle of retroviral replication. J Virol. 1994;68(7):4196–203.PubMed Burns DP, Temin HM. High rates of frameshift mutations within homo-oligomeric runs during a single cycle of retroviral replication. J Virol. 1994;68(7):4196–203.PubMed
32.
Zurück zum Zitat Young M, Inaba H, Hoyer LW, Higuchi M, Kazazian HH Jr, Antonarakis SE. Partial correction of a severe molecular defect in hemophilia A because of errors during expression of the factor VIII gene. Am J Hum Genet. 1997;60(3):565–73.PubMed Young M, Inaba H, Hoyer LW, Higuchi M, Kazazian HH Jr, Antonarakis SE. Partial correction of a severe molecular defect in hemophilia A because of errors during expression of the factor VIII gene. Am J Hum Genet. 1997;60(3):565–73.PubMed
33.
Zurück zum Zitat Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia. 2006;12(Suppl 6):15–22.CrossRefPubMed Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia. 2006;12(Suppl 6):15–22.CrossRefPubMed
34.
Zurück zum Zitat Tavassoli K, Eigel A, Pollmann H, Horst J. Mutational analysis of ectopic factor VIII transcripts from hemophilia A patients: identification of cryptic splice site, exon skipping and novel point mutation. Hum Genet. 1997;100(5–6):508–11.CrossRefPubMed Tavassoli K, Eigel A, Pollmann H, Horst J. Mutational analysis of ectopic factor VIII transcripts from hemophilia A patients: identification of cryptic splice site, exon skipping and novel point mutation. Hum Genet. 1997;100(5–6):508–11.CrossRefPubMed
35.
Zurück zum Zitat Gau JP, Hsu HC, Chau WK, Ho CH. A novel splicing acceptor mutation of the factor VIII gene producing skipping of exon 25. Ann Hematol. 2003;82(3):175–7.PubMed Gau JP, Hsu HC, Chau WK, Ho CH. A novel splicing acceptor mutation of the factor VIII gene producing skipping of exon 25. Ann Hematol. 2003;82(3):175–7.PubMed
36.
Zurück zum Zitat Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418–35.CrossRefPubMed Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418–35.CrossRefPubMed
37.
Zurück zum Zitat Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients—a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia. 1999;5(3):145–54.CrossRefPubMed Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients—a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia. 1999;5(3):145–54.CrossRefPubMed
38.
Zurück zum Zitat Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost. 1997;77(2):238–42.PubMed Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EG, Simpson E. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost. 1997;77(2):238–42.PubMed
39.
Zurück zum Zitat Hay CR, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost. 1997;77(2):234–7.PubMed Hay CR, Ollier W, Pepper L, Cumming A, Keeney S, Goodeve AC, et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost. 1997;77(2):234–7.PubMed
40.
Zurück zum Zitat Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK, MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood. 2006;107(8):3167–72.CrossRefPubMed Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK, MIBS Study Group. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood. 2006;107(8):3167–72.CrossRefPubMed
41.
Zurück zum Zitat Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood. 2006;108(12):3739–45.CrossRefPubMed Astermark J, Oldenburg J, Carlson J, Pavlova A, Kavakli K, Berntorp E, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood. 2006;108(12):3739–45.CrossRefPubMed
Metadaten
Titel
Mutation analysis of factor VIII in Korean patients with severe hemophilia A
verfasst von
Chur-Woo You
Hee-Sook Son
Hee Jin Kim
Eui-Jeon Woo
Soon-Ae Kim
Haing-Woon Baik
Publikationsdatum
01.06.2010
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 5/2010
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-010-0593-x

Weitere Artikel der Ausgabe 5/2010

International Journal of Hematology 5/2010 Zur Ausgabe

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.